Cited by 12Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesNeurotransmitter Receptor Influence on Behavior

Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial

Open access
Ang, Yuen-Siang, Bruder, Gerard E., Keilp, John G., Rutherford, Ashleigh, Alschuler, Daniel M., Pechtel, Pia, Webb, Christian A., Carmody, Thomas +11 more·2022·Psychological Medicine

Abstract

Background: Treatment for major depressive disorder (MDD) is imprecise and often involves trial-and-error to determine the most effective approach. To facilitate optimal treatment selection and inform timely adjustment, the current study investigated whether neurocognitive variables could predict an antidepressant response in a treatment-specific manner. Methods: In the two-stage Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) trial, outpatients with non-psychotic recurrent MDD were first randomized to an 8-week course of sertraline selective serotonin reuptake inhibitor or placebo. Behavioral measures of reward responsiveness, cognitive control, verbal fluency, psychomotor, and cognitive processing speeds were collected at baseline and week 1. Treatment responders then continued on another 8-week course of the same medication, whereas non-responders to sertraline or placebo were crossed-over under double-blinded conditions to bupropion noradrenaline/dopamine reuptake inhibitor or sertraline, respectively. Hamilton Rating for Depression scores were also assessed at baseline, weeks 8, and 16. Results: Greater improvements in psychomotor and cognitive processing speeds within the first week, as well as better pretreatment performance in these domains, were specifically associated with higher likelihood of response to placebo. Moreover, better reward responsiveness, poorer cognitive control and greater verbal fluency were associated with greater likelihood of response to bupropion in patients who previously failed to respond to sertraline. Conclusion: These exploratory results warrant further scrutiny, but demonstrate that quick and non-invasive behavioral tests may have substantial clinical value in predicting antidepressant treatment response.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s0033291720004286

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ang, Y.-S., Bruder, G. E., Keilp, J. G., Rutherford, A., Alschuler, D. M., Pechtel, P., Webb, C. A., Carmody, T., Fava, M., Cusin, C., McGrath, P. J., Weissman, M., Parsey, R., Oquendo, M. A., McInnis, M. G., Cooper, C. M., Deldin, P., Trivedi, M. H., & Pizzagalli, D. A.
Affiliations
  • Harvard University (US)
  • New York State Psychiatric Institute (US)
  • McLean Hospital (US)
  • The University of Texas Southwestern Medical Center (US)
  • Massachusetts General Hospital (US)
  • Stony Brook University (US)
  • University of Michigan (US)
Corresponding author
Pizzagalli, Diego A.
Venue
Psychological Medicine
Published
2020-11-20
Volume
52
Issue
13
Pages
2441-2449
ISSN
  • 0033-2917 (ISSN-L)
  • 1469-8978
OpenAlex
W3103697121
Cited by
12
References
64
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1
FWCI
0.75
Type
journal article
Language
en
Open access
Locations
  • Psychological Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Wellcome Trust (209581, 209581/Z/17/Z)
  • National Institute of Mental Health (U01MH092250, U01MH092221, R37MH068376)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
major depressive disorder, antidepressant response, bupropion, sertraline, neurocognitive predictors, reward responsiveness, cognitive control, verbal fluency, psychomotor speed, processing speed, treatment-resistant depression, placebo response, biosignatures
MeSH terms
Antidepressive Agents, Calcium Phosphates, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Humans, Bupropion, Treatment Outcome, Sertraline

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review